Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashish Gautam

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Indian Journal of Endocrinology and Metabolism|November 13, 2025
A Comparative Study to Evaluate the Association of Bisphenol-A in Gestational Diabetes Mellitus as Compared to Pregnant Women with Normal Glucose TolerancePrabhat K Agrawal, Shiv S Yadav, Ruchika Garg, et al.
British Journal of Haematology|September 22, 2018
Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United KingdomPaul J Bröckelmann, Suzanne McMullen, J Ben Wilson, et al.
Angiology|January 3, 2024
Fully Automated Agatston Score Calculation From Electrocardiography-Gated Cardiac Computed Tomography Using Deep Learning and Multi-Organ Segmentation: A Validation StudyAshish Gautam, Prashant Raghav, Vijay Subramaniam, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2005
Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevanceGerold Bepler, Zhong Zheng, Ashish Gautam, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
The Journal of the Association of Physicians of India|March 12, 2026
A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study)Prabhat Kumar Agrawal, Ketan K Mehta, Abhisekh Raha, et al.
BMC Endocrine Disorders|May 21, 2026
Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in IndiaNagendra Kumar Singh, Akash Kumar Singh, Arvind Gupta, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Indian Journal of Endocrinology and Metabolism|November 13, 2025
A Comparative Study to Evaluate the Association of Bisphenol-A in Gestational Diabetes Mellitus as Compared to Pregnant Women with Normal Glucose TolerancePrabhat K Agrawal, Shiv S Yadav, Ruchika Garg, et al.
British Journal of Haematology|September 22, 2018
Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United KingdomPaul J Bröckelmann, Suzanne McMullen, J Ben Wilson, et al.
Angiology|January 3, 2024
Fully Automated Agatston Score Calculation From Electrocardiography-Gated Cardiac Computed Tomography Using Deep Learning and Multi-Organ Segmentation: A Validation StudyAshish Gautam, Prashant Raghav, Vijay Subramaniam, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2005
Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevanceGerold Bepler, Zhong Zheng, Ashish Gautam, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.
Hematological Oncology|January 19, 2021
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 studyMartin Hutchings, John Radford, Stephen M Ansell, et al.
The Journal of the Association of Physicians of India|March 12, 2026
A Prospective Real-world Study to Assess Safety, Tolerability, and Effectiveness of Imeglimin among People with Type 2 Diabetes Mellitus Who are Intolerant to Metformin (PRISM Study)Prabhat Kumar Agrawal, Ketan K Mehta, Abhisekh Raha, et al.
BMC Endocrine Disorders|May 21, 2026
Real-world evidence of urinary tract infections and genital tract infections with sodium-glucose cotransporter-2 inhibitors (SGLT2i) alone or in combination with dipeptidyl peptidase-4 inhibitors (DPP4i) in individuals with type-2 diabetes mellitus in IndiaNagendra Kumar Singh, Akash Kumar Singh, Arvind Gupta, et al.
Pageof 4